FIG 7.
Luminespib inhibits virus growth and reduces P1-2A processing is a dose-dependent manner. (A) BHK-21 cells were treated with a 2.5-fold dilution series of luminespib and then infected with FMDV at an MOI of 0.01 (□) or mock infected (■) and incubated for 72 h at 37°C. Cell viability was determined by quantitating cellular ATP using a luminescence assay (Promega ToxGlo) and luminometer (Hidex Chameleon). (B) Cell-free expression reactions were pretreated with luminespib at the concentrations indicated prior to expression of radiolabeled P1-2A and processing by addition of purified 3Cpro. The samples were resolved through 12% SDS-PAGE gels and analyzed by fluorography.